



ASX ANNOUNCEMENT

Consultancy Arrangement

Melbourne, VIC. (28 September 2023) - Lumos Diagnostics (ASX:LDX, “Lumos” or the “Company”) today announces that it has entered into a consultancy agreement with Lumos’ Non-Executive Chair, Sam Lanyon, for the provision of advisory services in relation to investor relations, capital raising and commercialisation activities.

With CEO and Managing Director Doug Ward located in the United States, Lumos’ Board recognised the importance for an ASX-listed company to have an Australia-based resource that is able to assist with its capital market activities and to interface with the market in a timely manner. In addition to the payment of fees for his role as Non-Executive Chair of Lumos Diagnostics, Mr Lanyon will receive A\$80,000 per annum, based on an independent review and benchmarking evaluation conducted by SLM Corporate, for the provision of these additional advisory services. The agreement has been back-dated to be in effect from 1 July 2023 and can be terminated by either party with 4 weeks written notification.

-END-

###

This announcement has been approved by the Lumos Disclosure Committee.

About Lumos Diagnostics

Lumos Diagnostics specialises in rapid, cost-effective, and complete point-of-care (POC) diagnostic test technology to help healthcare professionals more accurately diagnose and manage medical conditions. Lumos offers customised assay development and manufacturing services for POC tests and proprietary digital reader platforms. Lumos also directly develops, manufactures, and commercialises novel Lumos-branded POC tests that target infectious and inflammatory diseases.

For more information visit lumosdiagnostics.com or call +1 941-556-1850.

Forward-Looking Statements

This announcement contains forward-looking statements, including references to forecasts. Forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, assumptions, and other important factors, many of which are beyond Lumos' control and speak only as of the date of this announcement. Readers are cautioned not to place undue reliance on forward-looking statements.

Media Contact:

Matthew Wright – Australia
Director, NWR Communications
matt@nwrcommunications.com.au
+61 (0) 451 896 420

Investor Contact:

Matthijs Smith – Lumos Diagnostics
ir@lumosdiagnostics.com
+61 3 9087 1598

Company Registered Office:

Lumos Diagnostics Holdings Ltd
Level 4, 100 Albert Rd
South Melbourne, VIC 3205
+61 3 9087 1598